Establishment of the Permeability Model for Soft Solid Sludge Conditioned with Flocculants

por Feng, Guohong, Bai, Tiantian, Ma, He, Hu, Zhi, Guo, Yabing, Tan, Wei
Publicado 2019

Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real...

por Wang, Kunyuan, Xia, Ying, Zhu, Yun, Yu, Wenxuan, Guo, Yabing, Liu, Li
Publicado 2021

Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma

por Han, Yanyan, Tao, Ran, Huang, Jin, Guo, Yabing, Wu, Dongyun, Liao, Yujing, Li, Jin, Zhou, Xiangjun, Hou, Jinlin
Publicado 2014

miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma

por Qin, Hongkun, Gui, Yanping, Ma, Rong, Zhang, Heng, Guo, Yabing, Ye, Yuting, Li, Jia, Zhao, Li, Wang, Yajing
Publicado 2021

Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study

por He, Yajing, Guo, Yabing, Chen, Jinzhang, Hu, Xiaoyun, Li, Xiaoshuang, Kong, Yanjun, Zhang, Xiaoyong, Zhou, Xiangjun, Liu, Li, Hou, Jinlin
Publicado 2018

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients

por Chen, Jinzhang, Hu, Xiaoyun, Li, Qi, Dai, Wencong, Cheng, Xiao, Huang, Wei, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Yuan, Guosheng
Publicado 2020

Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy

por Han, Yanyan, Wu, Yeting, Yang, Chou, Huang, Jing, Guo, Yabing, Liu, Li, Chen, Ping, Wu, Dongyun, Liu, Junyun, Li, Jin, Zhou, Xiangjun, Hou, Jinlin
Publicado 2017

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

por Li, Qi, Cao, Mengran, Yuan, Guosheng, Cheng, Xiao, Zang, Mengya, Chen, Ming, Hu, Xiaoyun, Huang, Jing, Li, Rong, Guo, Yabing, Ruan, Jian, Chen, Jinzhang
Publicado 2022

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients

por Yuan, Guosheng, Song, Yangda, Li, Qi, Hu, Xiaoyun, Zang, Mengya, Dai, Wencong, Cheng, Xiao, Huang, Wei, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Zhang, Qifan, Chen, Jinzhang
Publicado 2021

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

por Yuan, Guosheng, Cheng, Xiao, Li, Qi, Zang, Mengya, Huang, Wei, Fan, Wenzhe, Wu, Tao, Ruan, Jian, Dai, Wencong, Yu, Wenxuan, Chen, Mian, Guo, Yabing, Hu, Xiaoyun, Chen, Jinzhang
Publicado 2020

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial

por Qin, Shukui, Kudo, Masatoshi, Meyer, Tim, Bai, Yuxian, Guo, Yabing, Meng, Zhiqiang, Satoh, Taroh, Marino, Donatella, Assenat, Eric, Li, Songzi, Chen, Yaxi, Boisserie, Frederic, Abdrashitov, Ramil, Finn, Richard S., Vogel, Arndt, Zhu, Andrew X.
Publicado 2023

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multic...

por Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, Qin, Shukui
Publicado 2022

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

por Qin, Shukui, Chan, Stephen Lam, Sukeepaisarnjaroen, Wattana, Han, Guohong, Choo, Su Pin, Sriuranpong, Virote, Pan, Hongming, Yau, Thomas, Guo, Yabing, Chen, Minshan, Ren, Zhenggang, Xu, Jianming, Yen, Chia-Jui, Lin, Zhong-Zhe, Manenti, Luigi, Gu, Yi, Sun, Yongjian, Tiedt, Ralph, Hao, Lu, Song, Wenjie, Tanwandee, Tawesak
Publicado 2019

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

por Zhou, Jian, Sun, Huichuan, Wang, Zheng, Cong, Wenming, Zeng, Mengsu, Zhou, Weiping, Bie, Ping, Liu, Lianxin, Wen, Tianfu, Kuang, Ming, Han, Guohong, Yan, Zhiping, Wang, Maoqiang, Liu, Ruibao, Lu, Ligong, Ren, Zhenggang, Zeng, Zhaochong, Liang, Ping, Liang, Changhong, Chen, Min, Yan, Fuhua, Wang, Wenping, Hou, Jinlin, Ji, Yuan, Yun, Jingping, Bai, Xueli, Cai, Dingfang, Chen, Weixia, Chen, Yongjun, Cheng, Wenwu, Cheng, Shuqun, Dai, Chaoliu, Guo, Wengzhi, Guo, Yabing, Hua, Baojin, Huang, Xiaowu, Jia, Weidong, Li, Qiu, Li, Tao, Li, Xun, Li, Yaming, Li, Yexiong, Liang, Jun, Ling, Changquan, Liu, Tianshu, Liu, Xiufeng, Lu, Shichun, Lv, Guoyue, Mao, Yilei, Meng, Zhiqiang, Peng, Tao, Ren, Weixin, Shi, Hongcheng, Shi, Guoming, Shi, Ming, Song, Tianqiang, Tao, Kaishan, Wang, Jianhua, Wang, Kui, Wang, Lu, Wang, Wentao, Wang, Xiaoying, Wang, Zhiming, Xiang, Bangde, Xing, Baocai, Xu, Jianming, Yang, Jiamei, Yang, Jianyong, Yang, Yefa, Yang, Yunke, Ye, Shenglong, Yin, Zhenyu, Zeng, Yong, Zhang, Bixiang, Zhang, Boheng, Zhang, Leida, Zhang, Shuijun, Zhang, Ti, Zhang, Yanqiao, Zhao, Ming, Zhao, Yongfu, Zheng, Honggang, Zhou, Ledu, Zhu, Jiye, Zhu, Kangshun, Liu, Rong, Shi, Yinghong, Xiao, Yongsheng, Zhang, Lan, Yang, Chun, Wu, Zhifeng, Dai, Zhi, Chen, Minshan, Cai, Jianqiang, Wang, Weilin, Cai, Xiujun, Li, Qiang, Shen, Feng, Qin, Shukui, Teng, Gaojun, Dong, Jiahong, Fan, Jia
Publicado 2023